What has been agreed on Patent Box reforms?

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

What has been agreed on Patent Box reforms?

So, just five weeks after a UK government minister defended the country’s Patent Box scheme, George Osborne has announced that he has agreed with the German finance minister to make changes to it. But what changes has he agreed?

On October 3, Treasury minister David Gauke told the Securities Industries Conference that he rejected any suggestion that the UK’s Patent Box facilitates profit shifting.

“Let me be clear here: categorically, it does not create an opportunity for businesses to reduce their taxes without increasing their value to the UK economy.”

He went on to defend the use of a transfer pricing approach to the Patent Box, arguing that the so-called nexus approach – favoured by many of those EU governments that have been critical of the UK’s Patent Box scheme – could “infringe the freedom of establishment” and be “overly restrictive”.

The nexus approach would also require “incredibly detailed tracing of expenditure and income”, he said, placing a heavy burden on businesses and tax authorities.

It may not come as much surprise, therefore, to find that Osborne yesterday revealed in a joint statement with his German counterpart, finance minister Wolfgang Schauble, that they are proposing new rules based on a “nexus” approach.

(You can read more about the statement and reaction to it in an article by our sister magazine International Tax Review).

But what do the changes mean? I spoke to one patent attorney this morning who concluded that the wording of the statement – confusing and avoiding the term “patent box” completely – suggested that the UK Treasury had been caught off-guard. The Patent Box – at least as it is now formulated – is likely to be a casualty of wider EU machinations and behind-the-scenes negotiations between the UK and Germany over reform of the EU Treaty.

The inconclusive statement raises as many questions as it answers: it talks about closing the scheme to new entrants in 2016, and abolishing schemes by 2021, yet it doesn’t make clear whether the existing scheme will be changed to a nexus, rather than transfer pricing, approach within that timeframe.

We will try to get more information in the coming days about how the reforms – which will require legislative changes – will affect IP owners and their advisers. If you have insights into how they will work in practice do let us know.

more from across site and SHARED ros bottom lb

More from across our site

While business has been tough, foreign law firms with IP practices that have decided to stay put in China reveal why they are optimistic
Managing IP will host a ceremony in London on April 10 to reveal the winners of the EMEA Awards 2025
The Intellectual Property Judges' Association wrote to the European Commission just days before the proposals were shelved, it can be revealed
Karla Hughes and Adrian Dykes also join the former global IP head as partners in London, while another partner has left for Clifford Chance
A law firm restricting its employees’ use of AI, a leadership change at Siemens, and ‘probably’ the best trademark news Carlsberg could hope for, were among the top talking points
Former USPTO director Vidal, who rejoined Winston & Strawn after leaving the agency, explains why she got involved in an amicus brief related to jury instructions and Section 101
The judgment clarifies that being employed by a company does not necessarily undermine someone’s independence and ability to appear in court
The EU scrapping a controversial FRAND regulation gives the bloc a chance to properly engage with stakeholders to determine an appropriate way forward
Judd Lauter, who helped his client get a copyright registration for a creative work comprising of AI-generated parts, explains how his team obtained the registration
Ali Razai explains why he and his team joined the firm from Knobbe Martens and why he hopes to do ‘even more’ life sciences work
Gift this article